Glenmark Pharmaceuticals Deal History & Licensing Activity
Glenmark Pharmaceuticals is a large pharma headquartered in India. Over the past three years, Glenmark Pharmaceuticals has been involved in 1 licensing and acquisition transaction, with a primary focus on Adc Her2 (2 deals).
Deals (12mo)
2
Active Trials
14
Top Modality
Adc Her2
Focus Area
Oncology
Glenmark Pharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Glenmark Pharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| breast cancer | Hengrui Medicine | Adc Her2 | Phase 2 | license | Jul 2025 |
Glenmark Pharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Glenmark Pharmaceuticals is most active based on deal history and clinical trial data.
Glenmark Pharmaceuticals Strategic Signals
Key indicators of Glenmark Pharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Glenmark Pharmaceuticals's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Adc Her2 Benchmarks
Upfront, milestone, and royalty benchmarks for adc her2 deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Glenmark Pharmaceuticals Licensing & Deal Activity
Glenmark Pharmaceuticals is a large pharma company based in India that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Glenmark Pharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Glenmark Pharmaceuticals include Oncology (2 deals and trials). In terms of modality, Glenmark Pharmaceuticals has shown particular interest in adc her2.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Glenmark Pharmaceuticals and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Glenmark Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.